Join us to hear how the Greystar benefits team future-proofed their specialty care strategy by creating programs that connect the right employees with the right care while controlling surgery costs.
Understanding our relationship with food is crucial for driving behavior change and promoting long-term health, especially as we navigate the shifts brought on by GLP-1 medications and their impact on eating habits. But what underlying issues are influencing our connections with food, and how can we support tailored care at scale?
Trustmark Voluntary Benefits is ready to help you capitalize on the growing LTC market, offering a proven framework for high-impact care discussions that engage clients and drive revenue.
GLP-1 medications are transforming obesity care. Without addressing inactivity and muscle loss, employers risk a new wave of MSK claims. Up to 70% of GLP-1 users discontinue within a year, and many regain weight after treatment ends.
Join MBT's HR Manager, Ashley Neppl, and Alan Silver, president of Individual Coverage Health Reimbursement Arrangements (ICHRA) for Ambetter Health, to learn how to leverage the thriving individual health insurance market, control costs for good, and offer personalized benefits to every worker on your payroll.
Join us to learn the strategies driving success in 2025. Don't miss this opportunity to refine your approach to employee engagement, wellbeing, and ROI. Seats are limited, so secure yours now!
Aon data shows GLP-1 use over 2 years can cut employer medical costs by 7%. What's next for obesity meds, care delivery, and health outcomes? Explore the future of metabolic health and spending trends.
Most Total Rewards strategies check all the usual boxes—health, retirement, time off. But there's one area that still gets overlooked, and it's the one that can cause employees the most stress: their finances.
Navigating the cancer journey—from screening to treatment to survivorship—often means moving between multiple care teams. Too often, patients face breakdowns in coordination as they transition between primary care providers and oncology specialists.
